Remoxipride in the treatment of dopaminomimetic-therapy-induced psychosis in Parkinson's disease: Five case histories

Eriksson, Lars; Olsson, Josefine

doi:10.1016/0924-977x(93)90172-i

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, remoxipride, a relatively specific 02 receptor antagonist with some sigma receptor blocking properties (Kohler et al 1990) was also reported to reduce visual hallucinations and psychotic thinking in four of five Parkinson's disease patients receiving L-DOPA with or without bromocriptine or selegiline (Eriksson and Olsson 1993). One patient whose psychosis had responded to clozapine did not respond to remoxipride.…”

Section: Discussionmentioning

confidence: 99%

Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease

Meltzer

Kennedy

Dai

et al. 1995

Neuropsychopharmacol

View full text Add to dashboard Cite

The purpose of this study was to determine the plasma level of clozapine and its metabolite, N-desmethylclozapine, in Parkinson's disease patients with L-DOPA-induced psychosis responsive to clozapine. The psychotic symptoms of the three patients studied responded to low doses of clozapine with plasma levels of clozapine between 4.5 and 16.1 ng/ml and N-desmethylclozapine between 2.6 and 6.1 ng/ml, much below the plasma clozapine levels usually found in clozapine-treated refractory schizophrenia or affective disorders (range 100 to 687 ng/ml). Possible mechanisms that may account for clozapine's antipsychotic action in dopaminomimetic-induced psychosis in Parkinson's disease, including serotonin2A (5-HT2A) and dopamine D4 receptor blockade, at plasma levels that would be ineffective in refractory schizophrenia, are discussed. It is suggested that 5-HT2A receptor blockade is the most likely basis for the effectiveness of clozapine in L-DOPA psychosis.

show abstract

Section: Discussionmentioning

confidence: 99%